Biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided a scientific update on the advancement of its novel 5-HT2A psychedelic program for the treatment of mental diseases. Our 5-HT2A psychedelic drug discovery program is showing clear signs of success,? stated Dr. Alan Kozikowski, Ph.D., Chief Scientific Officer and Co-founder of Bright Minds. ?To date, we have synthesized hundreds of de novo, novel compounds in our discovery program and are currently optimizing a select handful of the most encouraging molecules to take into late preclinical development.